After A CRL Setback, Aldeyra Therapeutics Is A Compelling Speculative Buy

Core Viewpoint - Aldeyra Therapeutics, Inc. experienced a significant decline of 74% on April 3rd following the receipt of a Complete Response Letter from the FDA regarding its New Drug Application for reproxalap, intended for the treatment of dry eye disease [1] Company Summary - Aldeyra Therapeutics, Inc. is focused on developing reproxalap for dry eye disease, but faced a setback with the FDA's Complete Response Letter [1] - The company's stock performance was severely impacted, indicating potential investor concerns regarding the future of reproxalap and its market viability [1] Industry Context - The incident highlights the challenges faced by biotech companies in obtaining FDA approval, which can significantly affect stock prices and investor sentiment [1]